These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

474 related items for PubMed ID: 11756502

  • 21. Urocortin II gene is highly expressed in mouse skin and skeletal muscle tissues: localization, basal expression in corticotropin-releasing factor receptor (CRFR) 1- and CRFR2-null mice, and regulation by glucocorticoids.
    Chen A, Blount A, Vaughan J, Brar B, Vale W.
    Endocrinology; 2004 May; 145(5):2445-57. PubMed ID: 14736736
    [Abstract] [Full Text] [Related]

  • 22. The CRF Family of Neuropeptides and their Receptors - Mediators of the Central Stress Response.
    Dedic N, Chen A, Deussing JM.
    Curr Mol Pharmacol; 2018 May; 11(1):4-31. PubMed ID: 28260504
    [Abstract] [Full Text] [Related]

  • 23. Gestational hypoxia alone or combined with restraint sensitizes the hypothalamic-pituitary-adrenal axis and induces anxiety-like behavior in adult male rat offspring.
    Fan JM, Chen XQ, Jin H, Du JZ.
    Neuroscience; 2009 Apr 10; 159(4):1363-73. PubMed ID: 19409200
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Vital functions of corticotropin-releasing factor (CRF) pathways in maintenance and regulation of energy homeostasis.
    Carlin KM, Vale WW, Bale TL.
    Proc Natl Acad Sci U S A; 2006 Feb 28; 103(9):3462-7. PubMed ID: 16492754
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. The effect of urocortin I on the hypothalamic ACTH secretagogues and its impact on the hypothalamic-pituitary-adrenal axis.
    Bagosi Z, Csabafi K, Palotai M, Jászberényi M, Földesi I, Gardi J, Szabó G, Telegdy G.
    Neuropeptides; 2014 Feb 28; 48(1):15-20. PubMed ID: 24331779
    [Abstract] [Full Text] [Related]

  • 29. Expression of corticotropin releasing factor (CRF), urocortin and CRF type 1 receptors in hypothalamic-hypophyseal systems under osmotic stimulation.
    Imaki T, Katsumata H, Miyata M, Naruse M, Imaki J, Minami S.
    J Neuroendocrinol; 2001 Apr 28; 13(4):328-38. PubMed ID: 11264720
    [Abstract] [Full Text] [Related]

  • 30. Prenatal stress programs neuroendocrine stress responses and affective behaviors in second generation rats in a sex-dependent manner.
    Grundwald NJ, Brunton PJ.
    Psychoneuroendocrinology; 2015 Dec 28; 62():204-16. PubMed ID: 26318631
    [Abstract] [Full Text] [Related]

  • 31. Chronic administration of the selective corticotropin-releasing factor 1 receptor antagonist CP-154,526: behavioral, endocrine and neurochemical effects in the rat.
    Arborelius L, Skelton KH, Thrivikraman KV, Plotsky PM, Schulz DW, Owens MJ.
    J Pharmacol Exp Ther; 2000 Aug 28; 294(2):588-97. PubMed ID: 10900236
    [Abstract] [Full Text] [Related]

  • 32. Pharmacological evidence supporting a role for central corticotropin-releasing factor(2) receptors in behavioral, but not endocrine, response to environmental stress.
    Pelleymounter MA, Joppa M, Ling N, Foster AC.
    J Pharmacol Exp Ther; 2002 Jul 28; 302(1):145-52. PubMed ID: 12065711
    [Abstract] [Full Text] [Related]

  • 33. Strain differences in anxiety-like behavior: association with corticotropin-releasing factor.
    Shepard JD, Myers DA.
    Behav Brain Res; 2008 Jan 25; 186(2):239-45. PubMed ID: 17904655
    [Abstract] [Full Text] [Related]

  • 34. Regulation of the developing hypothalamic-pituitary-adrenal axis in corticotropin releasing hormone receptor 1-deficient mice.
    Schmidt MV, Oitzl MS, Müller MB, Ohl F, Wurst W, Holsboer F, Levine S, De Kloet ER.
    Neuroscience; 2003 Jan 25; 119(2):589-95. PubMed ID: 12770571
    [Abstract] [Full Text] [Related]

  • 35. The effects of corticotropin-releasing factor and the urocortins on hypothalamic gamma-amino butyric acid release--the impacts on the hypothalamic-pituitary-adrenal axis.
    Bagosi Z, Csabafi K, Jászberényi M, Telegdy G.
    Neurochem Int; 2012 Mar 25; 60(4):350-4. PubMed ID: 22306347
    [Abstract] [Full Text] [Related]

  • 36. Role of corticotropin-releasing factor and corticosterone in behavioral sensitization to ethanol.
    Pastor R, Reed C, Meyer PJ, McKinnon C, Ryabinin AE, Phillips TJ.
    J Pharmacol Exp Ther; 2012 May 25; 341(2):455-63. PubMed ID: 22333290
    [Abstract] [Full Text] [Related]

  • 37. The blockade of corticotropin-releasing factor 1 receptor attenuates anxiety-related symptoms and hypothalamus-pituitary-adrenal axis reactivity in mice with mild traumatic brain injury.
    Kosari-Nasab M, Sadeghi T, Bashiri H, Shokouhi G, Salari AA.
    Behav Pharmacol; 2019 Apr 25; 30(2 and 3-Spec Issue):220-228. PubMed ID: 30883392
    [Abstract] [Full Text] [Related]

  • 38. The blockage of ventromedial hypothalamus CRF type 2 receptors impairs escape responses in the elevated T-maze.
    Silva MSCF, Souza TMO, Pereira BA, Ribeiro DA, Céspedes IC, Bittencourt JC, Viana MB.
    Behav Brain Res; 2017 Jun 30; 329():41-50. PubMed ID: 28435125
    [Abstract] [Full Text] [Related]

  • 39. Cardiac CRFR1 Expression Is Elevated in Human Heart Failure and Modulated by Genetic Variation and Alternative Splicing.
    Pilbrow AP, Lewis KA, Perrin MH, Sweet WE, Moravec CS, Tang WH, Huising MO, Troughton RW, Cameron VA.
    Endocrinology; 2016 Dec 30; 157(12):4865-4874. PubMed ID: 27754786
    [Abstract] [Full Text] [Related]

  • 40. Localization of agonist- and antagonist-binding domains of human corticotropin-releasing factor receptors.
    Liaw CW, Grigoriadis DE, Lorang MT, De Souza EB, Maki RA.
    Mol Endocrinol; 1997 Dec 30; 11(13):2048-53. PubMed ID: 9415408
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 24.